Cite

    Wang, S. et al. (2017). Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis and cartilage. 25 (12), pp. 1952-1961. [Online].